Molecular Axiom

Molecular Axiom is a precision nucleic acid medicine company focused on developing innovative target delivery therapies for the treatment of complex diseases, with a particular emphasis on pancreatic cancer, neurodegenerative diseases, and metabolism. Founded in 2022 and headquartered in the United States, the company aims to redefine the treatment landscape for these ailments. Molecular Axiom's proprietary bifunctional nucleic acid medicine addresses targeted delivery and inhibition of genetic mutant targets, offering a unique approach to combating these challenging conditions. With a focus on biopharma and biotechnology industries, Molecular Axiom presents an intriguing opportunity for venture capital firms seeking to invest in groundbreaking approaches to disease treatment. As of now, there is no public information available regarding the company's last investment or the involved investors.